Amicus Therapeutics, Inc. (FOLD) is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). It has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. It is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa. It has also initiated a clinical study in patients with Pompe disease, a LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with AT2221, to improve activity and stability.
Down 6.5% today, and another 26% after hours. Looks like most analysts are upgrading them or reiterating higher targets, not sure why it's down. EDIT: Found this article as well: Amicus Therapeutics announces U.S. Regulatory pathway for Migalastat for Fabry Disease Source: http://www.reuters.com/article/idUSFWN1DT0PN
it needs a bit updated here Amicus Therapeutics Receives Rare Pediatric Disease Designation for SD-101 for Patients with Epidermolysis Bullosa https://finance.yahoo.com/news/amicus-therapeutics-receives-rare-pediatric-113000615.html May-19-17 07:30AM Amicus Therapeutics Announces Planned Analysis of Primary Endpoints in Phase 3 Epidermolysis Bullosa Study GlobeNewswire May-18-17 08:00AM Today's Research Reports on Biotech Stocks to Watch: Exelixis and Amicus Therapeutics Accesswire May-15-17 07:00AM Amicus Therapeutics Announces Positive Functional Data from Initial Patients in Pompe Phase 1/2 Study GlobeNewswire May-10-17 08:36AM Edited Transcript of FOLD earnings conference call or presentation 9-May-17 12:30pm GMT Thomson Reuters StreetEvents 07:30AM Amicus Therapeutics to Present at Two Upcoming Investor Conferences GlobeNewswire May-09-17 04:37PM ETFs with exposure to Amicus Therapeutics, Inc. : May 9, 2017 Capital Cube 08:57AM Amicus Therapeutics reports 1Q loss Associated Press 08:15AM Investor Network: Amicus Therapeutics, Inc. to Host Earnings Call Accesswire 07:30AM Amicus Therapeutics Announces First Quarter 2017 Financial Results and Corporate Updates GlobeNewswire
I always said (to myself when under $6) to play FOLD long instead to scalp it in pre high 14.95 closed 10.26 news >>>http://www.marketwatch.com/story/am...treatment-2017-07-11?siteid=yhoof2&yptr=yahoo
